Myasthenia Gravis Drug Pipeline Shows Activity with Over 28 Companies
A market analysis report indicates over 28 companies are developing new treatments for myasthenia gravis. Multiple drug candidates are in clinical trials, with some progressing to later stages.
Albany, US – September 29, 2026 – Over 28 companies are actively engaged in developing new treatments for myasthenia gravis, a chronic autoimmune disorder affecting the neuromuscular junction. A new analysis report, "Myasthenia Gravis – Pipeline Insight, 2026" by DelveInsight, identifies more than 30 drug candidates in the pipeline.
The report provides comprehensive data on the research and development landscape for myasthenia gravis. It details clinical and non-clinical stage products, evaluating them by product type, development stage, route of administration, and molecule type. The analysis also identifies inactive pipeline projects.
Companies involved in the development include Dianthus Therapeutics, Novartis AG, Bristol-Myers Squibb, and Roivant Sciences, among others. Several drug candidates, such as Claseprubart (DNTH103) and IM-101, have advanced to later-stage clinical trials, with some reaching Phase III.
Myasthenia gravis is characterized by fluctuating skeletal muscle weakness due to the immune system attacking the neuromuscular junction. While there is no cure, existing treatments aim to manage symptoms and suppress the autoimmune response. The progression of new therapies in clinical trials offers potential for improved management of the condition.
The ongoing research and development signify a focused effort to address unmet needs in myasthenia gravis treatment. The report highlights the diverse approaches being taken by pharmaceutical companies to bring novel therapies to patients.